Leukocyte Poor PRP vs Leukocyte Rich PRP: 6 Essential Questions Before You Order

Leukocyte poor PRP and leukocyte rich PRP are the same autologous preparation taken to two different endpoints. The difference is how much of the patient’s white cell fraction ends up in the final volume, and the definition is relative rather than absolute. A leukocyte rich preparation carries a leukocyte concentration above that patient’s own whole blood baseline, and leukocyte poor PRP carries one below it. Because the reference point is the patient rather than a fixed count, two kits can both be described as leukocyte poor PRP systems and still hand a practice measurably different products.

For a practice buying kits, tubes and a centrifuge, that is a purchasing question before it is anything else. The leukocyte fraction is decided by the separation, and the separation is decided by the kit geometry, the draw volume, the spin protocol and the machine the tubes are spun in. Change the machine or the protocol and the product changes with it, whatever the label says. This guide covers what the two terms mean, which published classification systems record leukocyte content, what survey data shows practices actually stock, and the questions worth asking a supplier before a first order.

What is the difference between leukocyte poor PRP and leukocyte rich PRP?

Both start from the same place. A volume of the patient’s blood is drawn into a prepared tube and spun, the components separate by density, and the platelet bearing plasma is drawn off. Red cells settle to the bottom. White cells concentrate in the thin buffy coat layer that sits between the red cells and the plasma. Whether that buffy coat is collected, partly collected or left behind is what separates a leukocyte rich preparation from leukocyte poor PRP.

The literature is consistent on the principle and loose on the number. Leukocyte rich means a leukocyte concentration above the patient’s baseline whole blood value; leukocyte poor PRP means one below it. Some coding schemes add a cut point. The PLRA scheme summarised in the 2021 EFORT Open Reviews narrative review by Collins, Alexander and Barkatali scores leukocyte content as present or absent at a threshold of one percent. Others simply record the measured concentration and leave the reader to judge. None of them is universal, which is the first thing to know when comparing two specification sheets.

It follows that the phrase on a box is a description of intent, not a specification. When a kit is marketed as a leukocyte poor PRP system, a practice that wants to know what it is actually buying has to look at the reported cell counts and the protocol they were measured under, and those are not always published.

Why do two systems with the same label produce different preparations?

Because the category is far less standardised than its vocabulary suggests, and the published evidence on that point is unusually blunt.

Magalon and colleagues reviewed the technical and biological literature on commercial PRP devices for Platelets in 2021. Screening 1,379 studies and retaining 105 for technical analysis, they identified 50 commercial PRP preparation systems in use (Magalon et al., Platelets, 2021). Of those 50, only 14 had been described in enough biological detail anywhere in the literature to characterise what they actually produce. Their conclusion was that comparison across the category reveals large heterogeneity, and that the absence of biological quality control is a plausible explanation for how variable the reported results have been.

The same group had already quantified part of that spread. Introducing the DEPA classification in BMJ Open Sport & Exercise Medicine in 2016, they applied it retrospectively to 20 PRP preparations described in the literature. The dose of injected platelets ranged from 0.21 billion to 5.43 billion, a 25-fold difference between the lowest and the highest, and no device in that set recovered more than 90 percent of the platelets from the blood drawn.

Leukocyte content behaves the same way. If platelet dose varies 25-fold between systems that are all sold as PRP, then a label reading leukocyte poor PRP is not carrying much information on its own. What carries information is a measured count, the protocol it was measured under, and whether the practice can reproduce that protocol on its own bench. Treat leukocyte poor PRP as a claim to be checked rather than a specification already met.

Which PRP classification systems record leukocyte content?

Several, and they disagree about where leukocytes sit in the hierarchy. The table below covers the schemes a physician is most likely to meet in a product brochure or a journal methods section.

The PAW system is the most widely cited of these in orthopaedics. DeLong, Russell and Mazzocca proposed it in Arthroscopy in 2012, arguing that preparation protocols vary widely between authors and are often poorly documented, which makes published results difficult to compare or replicate. Their fix was to record three things: the absolute number of platelets, the manner of activation, and the presence or absence of white cells. More than a decade later, the common experience is still a product sheet that reports none of the three.

For a purchasing conversation, the value of these schemes is not that a practice needs to adopt one. It is that they name the variables a supplier can reasonably be asked about when a kit is offered as a leukocyte poor PRP system, and they give both sides a shared vocabulary for the answer.

What do sports medicine physicians report stocking?

The most useful survey data on this comes from Noback and colleagues, published in JAAOS Global Research & Reviews in 2021. They surveyed 599 members of the American Orthopaedic Society for Sports Medicine and analysed 165 complete responses, a 27.5 percent completion rate. Leukocyte poor PRP came out ahead, though by a narrower margin than the term’s prominence might suggest.

• Of the 165 respondents, 109 (66.1 percent) reported using at least one orthobiologic in practice.
• Among those 109, the most commonly used product was leukocyte poor PRP, reported by 83 respondents (76.1 percent).
• Leukocyte rich PRP followed at 77 respondents (70.6 percent).

The overlap is the part worth reading twice. Those two figures add to well over 100 percent, so a large share of the respondents were using both. That is a fair description of how these programs run: the formulation is chosen case by case by the treating physician, and the practice stocks for whichever protocols its clinicians use. A supply arrangement built around leukocyte poor PRP alone can turn into a problem the first time a partner physician works differently.

How do the kit and the spin protocol decide leukocyte content?

The separation is a mechanical event, and everything that changes the mechanics changes the result. Spin speed and duration set how far the layers migrate. Rotor geometry sets the angle the boundary forms at. Tube shape and volume set how much room the buffy coat has. The draw itself matters too, because the starting haematocrit is the patient’s own. Nothing about leukocyte poor PRP is fixed by the label on the box. It is produced on the bench, spin by spin.

This is why manufacturers validate a kit against a specific centrifuge and a specific protocol, and why running the same kit at a different speed on a borrowed machine is not the same procedure. A practice that wants a reproducible leukocyte poor PRP protocol needs the machine, the tubes and the written protocol to stay fixed together, and it needs whoever runs the spin on a Tuesday to run it the same way on a Friday.

There is a documentation gap here that shows up as soon as anyone tries to check the detail. Rotor type is a good example. When HealthWright Technologies built out its Juventix product pages in August 2026, the manufacturer specifications available for the VitalitySpin CENT8 covered capacity, speed range, timer, safety interlocks and warranty, but did not state the rotor type; the CENT4-XL is published as a swing bucket design. The specifications supplied for the Medical PRP Kit line likewise described red cell exclusion, sterility, spin time and shelf life, and did not assign the kits a leukocyte classification. Neither omission is unusual for the category. Both are worth asking about rather than assuming.

What should a practice ask before ordering PRP kits?

Six questions cover most of what a specification sheet leaves out when a kit is presented as a leukocyte poor PRP system. None of them is a clinical question, and a supplier should be able to answer all six or say plainly that the manufacturer does not publish the figure.

1. What leukocyte classification, if any, does the manufacturer assign the kit? If the answer is none, that is still a usable answer. It tells you the leukocyte poor PRP description is marketing language rather than a measured specification.
2. Under what protocol were the reported cell counts measured? A platelet or leukocyte figure with no spin speed, spin time and machine attached to it cannot be reproduced or compared.
3. Which centrifuge was the kit validated against? Kit and machine are validated as a pair. Mixing a kit from one manufacturer with a machine from another moves the result in ways nobody has measured.
4. What is the rotor type and the usable speed range? Fixed angle and swing bucket rotors form the separation boundary differently, so a protocol written for one is not automatically valid on the other.
5. What are the storage conditions and the shelf life? This drives how much stock a practice can hold and how often it reorders, which is the difference between a program that runs smoothly and one that reschedules appointments.
6. Where does the regulatory clearance sit, and what does it cover? Clearance attaches to the preparation device and its stated indication, not to a clinical use. Ask for the wording rather than a summary of it.

Where does device clearance fit in the leukocyte question?

Alongside it, rather than answering it. The device clearance and the clinical therapy are separate regulatory matters, and running the two together is the most common error in PRP marketing copy.

Preparation devices in this category are regulated as medical devices. In the FDA device classification database, product code ORG is defined as a “Platelet And Plasma Separator For Bone Graft Handling,” a Class II device under 21 CFR 864.9245, reviewed by the hematology panel. The database records its intended use as the “preparation of autologous platelet rich plasma from a small sample of peripheral blood for mixing with bone graft to improve handling characteristics.” Nothing in that definition speaks to leukocyte content, so a clearance record will never tell you whether a kit yields leukocyte poor PRP, and nothing in it speaks to any clinical indication beyond the one stated.

The manufacturer’s own statement is worth reading whole rather than in the first sentence only, which is where most summaries stop. Juventix Regenerative Medical states that its Medical PRP Kit line consists of FDA 510(k)-cleared Class II medical devices intended for the safe and rapid preparation of autologous platelet-rich plasma from a small sample of blood at the patient point of care, with the PRP mixed with autograft or allograft bone prior to application to a bony defect for improving handling characteristics. Juventix states that all other applications of PRP are considered off-label and are not recommended or endorsed by the manufacturer. Any clinical use is the treating provider’s decision and responsibility.

HealthWright Technologies reports that statement as the manufacturer makes it and does not extend it. It is set out in the same form, with the manufacturer’s own verification pointers, on the Juventix PRP kits page.

The practical reading is short. Clearance tells you a preparation device met a regulatory standard for a stated purpose. It does not tell you whether the output is leukocyte poor PRP, it does not tell you the platelet dose, and it does not endorse any particular clinical use. Those remain separate questions, and the first two belong on the purchasing checklist above.

Sourcing kits, tubes and a matched centrifuge

HealthWright Technologies supplies the Juventix PRP line to licensed medical practices nationwide: the Medical PRP kits and tubes in 12 mL, 15 mL and 30 mL XL formats, and the VitalitySpin centrifuges the manufacturer designed to run them. Because the kits and the machine come from the same manufacturer, the spin protocol and the consumables stay aligned, and a practice has one reorder point instead of three.

If you are still scoping a program rather than reordering for one, our overview of what a practice needs to add PRP walks through the equipment list, and our guide to choosing a PRP centrifuge covers the machine decision in more detail. Whether a given protocol yields leukocyte poor PRP or a leukocyte rich preparation stays with the clinician and the protocol; what a supplier can keep steady is what sits behind it. Practices building a broader non-narcotic service line often pair PRP with Hako-Med electrotherapy systems.

These items are sold to licensed healthcare providers and facilities. Apply once for a provider account and we will email your login details once it is approved. For anything the product pages do not answer, email contact@healthwrighttechnologies.com or use the contact page and we will follow up. HealthWright Technologies is at 60 Bear Creek Marina Road, Mansfield, GA 30055.

Frequently asked questions about leukocyte poor PRP

Is leukocyte poor PRP the same as pure PRP?

Not quite, though the terms overlap. In the 2009 Dohan Ehrenfest framework, pure platelet rich plasma (P-PRP) is the leukocyte poor family, and leukocyte and platelet rich plasma (L-PRP) is the leukocyte rich family. The same framework splits both again by whether the product is a liquid plasma or a dense fibrin matrix. Newer systems such as PAW, DEPA and MARSPILL report leukocyte content as one measured variable rather than as a family name, which is why a kit can be described as leukocyte poor PRP in marketing copy and still carry no formal classification anywhere in its specification sheet.

How is leukocyte poor PRP measured?

Against the patient, not against a fixed number. A preparation is leukocyte poor when its leukocyte concentration falls below that patient’s own whole blood baseline, and leukocyte rich when it sits above it. Some coding schemes add a numeric cut. The PLRA scheme summarised in EFORT Open Reviews scores leukocyte content as present or absent at a one percent threshold. Confirming which convention a supplier used is the only way to compare two specification sheets honestly.

Does the centrifuge change whether a preparation is leukocyte poor PRP?

Yes. Leukocyte content is decided by where the separation boundary falls and how cleanly the layers hold, so spin speed, spin time, rotor geometry and tube shape all move it. A kit validated on one machine and one protocol is not automatically the same product on a different machine. That is the practical argument for running the kits, tubes and centrifuge a manufacturer designed together, and for writing the protocol down so the result is reproducible between staff.

Do PRP kits state a leukocyte classification?

Often not. When HealthWright Technologies assembled its Juventix product pages in August 2026, the manufacturer specifications available covered red cell exclusion, sterility, spin time and shelf life, and did not assign the Medical PRP Kit line a leukocyte classification under PAW, DEPA or MARSPILL. That is common across the category rather than unusual, and it is exactly why the question belongs on a purchasing checklist.

Which formulation should a practice stock?

That is a clinical decision for the treating provider and it sits outside what a supplier can answer. HealthWright Technologies supplies equipment and consumables and makes no recommendation between leukocyte poor PRP and leukocyte rich preparations. What a supplier can help with is the procurement side: which kits and tubes a program consumes, which centrifuge matches them, and how reorders are handled.

This article describes equipment and supplies only and makes no treatment claims. HealthWright Technologies does not recommend leukocyte poor PRP or leukocyte rich PRP for any condition; the choice of preparation, and every clinical decision about its use, rests with the treating provider. Consult your healthcare provider before starting any new treatment. Regulatory statements about the Juventix line are reported as the manufacturer makes them.